On December 9, the "2022 High-Quality Development Conference of the Great Health Industry and the 7th China Pharmaceutical R&D and Innovation Summit" was held online. The conference, co-organized by YAOZH.COM and China Pharmaceuticals Magazine, featured the publication of the "2022 China Pharmaceutical Industry R&D Strength Ranking Series List". As a world-leading one-stop platform for drug R&D and production services, Viva Biotech was awarded "Top 20 Chinese R&D CRO Enterprises in 2022" and placed sixth on the list. Additionally, Viva's subsidiary, Langhua Pharmaceutical, was recognized as one of the "Top 20 Chinese CDMO Enterprises in 2022".
The "Top 20 Chinese CRO/CDMO Enterprises in 2022" lists are based on strict criteria, including ten indicators such as the company's total annual revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, personnel size, personnel growth, brand awareness, and leadership in specific fields. These indicators represent the highest level of excellence in the pharmaceutical CRO/CDMO industry.
Viva Biotech and its subsidiary Langhua Pharmaceutical have been recognized for their comprehensive strength in the pharmaceutical industry, winning two awards in a row at the "2022 High-Quality Development Conference of the Great Health Industry and the 7th China Pharmaceutical R&D and Innovation Summit". Viva Biotech is a one-stop platform for drug development, providing global innovative drug R&D companies with comprehensive services from SBDD to commercial drug delivery. This year, the company successfully completed the construction of its new headquarters for the integration of drug R&D. By building advanced technology platforms, a first-class R&D team, and complete operating facilities, Viva Biotech aims to create more comprehensive services throughout the industry chain, empowering the innovation and development of biomedicine. The company continues to expand its team of scientific talent and scale its operations, with more than 2,300 employees worldwide and R&D centers in multiple cities in China and branches in 10 countries to quickly respond to global market needs.
In the future, Viva Biotech will continue to develop its one-stop platform for drug R&D and production services, deepen the synergy between its CRO and CDMO businesses, and actively create an open cooperation platform and win-win ecosystem for global biopharmaceutical innovators. By doing so, the company aims to contribute to the innovation and development of the pharmaceutical industry.
About Viva Biotech
Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.
As of June 30, 2022, Viva Biotech has provided drug R&D and production services to 1,947 biotech and pharmaceutical clients around the world. We have invested and incubated 90 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.
About Langhua Pharmaceutical
Zhejiang Langhua Pharmaceutical Co., Ltd, is a comprehensive pharmaceutical company engaged in research and development, production, marketing and sourcing of pharmaceutical products. As the subsidiary of world leading drug discovery CRO company Viva Biotech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.